

Introducing Biosimilar-Related Technologies at the Bio Japan 2011 Exhibition

Toyobo subsidiary Toyobo Biologics Inc. ("TBI") will be operating an exhibit booth at the "Bio Japan 2011" exhibition held from October 5 (Wednesday) through 7 (Friday), 2011, at the PACIFICO Yokohama site.

Details

1. Exhibit Booth

- (1) Exhibition Dates: October 5 (Wednesday) through 7 (Friday), 2011
- (2) Exhibition Site: PACIFICO Yokohama (Nishi-ku, Yokohama), Booth: S504
- (3) Exhibit Content
- ① Introducing a comprehensive menu of commissioned biosimilar development services
- Cell-bank production technology, mainly for biosimilar antibody drugs GPEx[®] technology of U.S.-based Catalent Pharma Solutions, Inc. UCOE™ technology of EMD Millipore
- Contract manufacturing of biosimilar antibody drugs
- Contract viral safety testing and evaluation for biopharmaceuticals
- ② Introducing contract development services for new biologics drugs other than biosimilar antibody drugs

In addition to mammalian cell culturing, TBI offers contract manufacturing of new biologics based on microbial fermentation .

2. About Toyobo Biologics Inc.

Established by Toyobo in 2001, Toyobo Biologics Inc. (TBI) employs genetic recombination technologies accumulated during a period of more than 30 years in

connection with Toyobo's life sciences business and pharmaceuticals business to provide a comprehensive and integrated array of commissioned services for processes ranging from early-development-stage mammalian cell and microorganism culturing through production and quality assurance. Particularly with respect to commissioned work handling processes from the development through the production of biosimilars centered on antibody drugs, which have attracted considerable attention in recent years, TBI has been strengthening its alliances with Japan- and overseas-based companies and upgrading its own technologies, aiming to be the global category leader.

For more information, contact:
The Toyobo Public Relations Group

pr g@toyobo.jp